How should I evaluate and treat a patient with suspected Curvularia infection and enterovirus infection?

Curvularia and Enterovirus Co-Infection Management

For suspected Curvularia infection, immediately obtain tissue biopsy for histopathology, culture, and fungal sequencing (ITS/LSU regions), initiate aggressive surgical debridement if invasive disease is present, and start empiric antifungal therapy with amphotericin B or an azole (itraconazole/posaconazole) pending susceptibility results; for enterovirus, diagnose using RT-PCR targeting the 5'NCR region from multiple specimen types (CSF, respiratory samples, stool, and blood depending on clinical presentation), as there is no specific antiviral therapy approved for routine use.

Diagnostic Approach for Curvularia

Immediate Evaluation

• Obtain tissue biopsy from affected sites (sinus, eye, lung, or other involved tissue)
• Send specimens for:
  • Histopathology (look for dematiaceous fungal elements)
  • Fungal culture
  • Molecular identification via ITS and LSU ribosomal DNA sequencing 1, 2, 3
  • Antifungal susceptibility testing (AFST) once organism is isolated

Key Clinical Pitfall

Curvularia identification by microscopy alone is unreliable due to overlapping morphological features among species 3. Molecular sequencing is essential for accurate species identification, which directly impacts treatment decisions since different Curvularia species show variable antifungal susceptibility 1.

Risk Stratification

• Immunocompromised patients (hematologic malignancy, transplant recipients): Higher risk for invasive disease 2
• Immunocompetent patients: Can still develop invasive sinusitis with intracranial extension 1
• Delayed presentation significantly worsens prognosis 1

Diagnostic Approach for Enterovirus

Specimen Collection Strategy

Collect multiple specimen types simultaneously based on clinical presentation 4:

For Neurological Infections (Meningitis/Encephalitis/Myelitis):

• CSF (primary specimen)
• Respiratory sample (nasopharyngeal swab/aspirate) - critical because EV-D68 and EV-A71 are often undetectable in CSF 4
• Stool specimen
• Blood/plasma (viral load can be higher in blood than CSF in some cases) 4

For Neonatal Sepsis:

• CSF, stool, blood, AND respiratory sample 4

For Myocarditis:

• Stool and respiratory samples
• Blood
• Consider heart biopsy if diagnosis unclear 4

Laboratory Testing

• Use RT-PCR targeting the 5'NCR region for diagnosis - this is the gold standard due to sensitivity, specificity, and rapid turnaround 4, 5
• For typing: Sequence VP1 capsid protein gene (not 5'NCR due to recombination events) 4
• Do NOT rely on viral culture - it is time-consuming and less sensitive 5
• Also test for human parechovirus if enterovirus is negative, especially in neonates (requires separate NAAT) 4, 5

Critical Timing

Sample collection should occur as soon as possible after symptom onset (incubation period 3-21 days) 4

Treatment Approach

Curvularia Management

Combination surgical and medical therapy is essential 1, 6, 2:

1. Surgical intervention:

   • Aggressive debridement of infected tissue
   • Multiple interventions may be necessary 6
   • Early surgical intervention improves outcomes 1

2. Antifungal therapy:

   • Empiric options (pending AFST):
     • Amphotericin B (typical MIC 1 µg/mL) 1
     • Itraconazole (typical MIC 0.25 µg/mL) 1
     • Posaconazole (typical MIC 0.125 µg/mL) 1
   • Adjust based on susceptibility results
   • Curvularia shows relatively low virulence compared to other angioinvasive molds when treated appropriately 2

3. Duration: Prolonged therapy required; continue until clinical and radiological resolution

Enterovirus Management

No FDA-approved antiviral therapy is available for routine clinical use 5, 7:

• Supportive care is the mainstay for most enterovirus infections
• Most infections are self-limited 4, 7
• Pleconaril (investigational): Has been used on compassionate-release basis for potentially life-threatening infections with favorable responses in 78% of patients 8, but is not routinely available
• Monitor for severe manifestations:
  • Meningoencephalitis, myelitis, acute flaccid paralysis (especially EV-A71, EV-D68) 4
  • Neonatal sepsis, myocarditis 4
  • These presentations carry significant morbidity and mortality 4

Key Clinical Pearls

For Curvularia:

• Late presentation and delayed antifungal therapy are associated with mortality 1
• High index of suspicion needed, especially in patients with chronic sinusitis not responding to standard therapy
• Even immunocompetent patients can develop invasive disease 1

For Enterovirus:

• EV-D68 is rarely detectable in CSF or stool - respiratory specimens are critical 4
• Young age increases risk of severe outcomes 4
• Detection in throat/stool provides only circumstantial evidence of CNS infection unless CSF is also positive 5
• Serology is not useful for acute diagnosis due to high seroprevalence 5, 7

Co-infection Considerations:

These are distinct pathogens requiring separate diagnostic and therapeutic approaches. Curvularia requires aggressive intervention; enterovirus typically requires supportive care unless life-threatening manifestations develop.